Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I Study of Anti-IGF-1R Monoclonal Antibody, IMC-A12, and mTOR Inhibitor, Everolimus, in Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT01204476
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:36:10.596827+00:00
Published At
2016-07-15T00:00:00+00:00
Record Updated At
2016-07-15
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Gastrin-Producing Neuroendocrine Tumor", "Lung Carcinoid Tumor", "Metastatic Digestive System Neuroendocrine Tumor G1", "Pancreatic Glucagonoma", "Pancreatic Insulinoma", "Pancreatic Polypeptide Tumor", "Paraganglioma", "Recurrent Digestive System Neuroendocrine Tumor G1", "Recurrent Merkel Cell Carcinoma", "Recurrent Pancreatic Neuroendocrine Carcinoma", "Regional Digestive System Neuroendocrine Tumor G1", "Somatostatin-Producing Neuroendocrine Tumor", "Stage III Merkel Cell Carcinoma", "Stage IV Merkel Cell Carcinoma", "Thyroid Gland Medullary Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2016-07-15"
protocolSection.identificationModule.nctId
"NCT01204476"
protocolSection.identificationModule.officialTitle
"Phase I Study of Anti-IGF-1R Monoclonal Antibody, IMC-A12, and mTOR Inhibitor, Everolimus, in Advanced Low to Intermediate Grade Neuroendocrine Carcinoma"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Gastrin-Producing Neuroendocrine Tumor (protocolSection.conditionsModule.conditions)
  • Lung Carcinoid Tumor (protocolSection.conditionsModule.conditions)
  • Metastatic Digestive System Neuroendocrine Tumor G1 (protocolSection.conditionsModule.conditions)
  • Pancreatic Glucagonoma (protocolSection.conditionsModule.conditions)
  • Pancreatic Insulinoma (protocolSection.conditionsModule.conditions)
  • Pancreatic Polypeptide Tumor (protocolSection.conditionsModule.conditions)
  • Paraganglioma (protocolSection.conditionsModule.conditions)
  • Recurrent Digestive System Neuroendocrine Tumor G1 (protocolSection.conditionsModule.conditions)
  • Recurrent Merkel Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Pancreatic Neuroendocrine Carcinoma (protocolSection.conditionsModule.conditions)
  • Regional Digestive System Neuroendocrine Tumor G1 (protocolSection.conditionsModule.conditions)
  • Somatostatin-Producing Neuroendocrine Tumor (protocolSection.conditionsModule.conditions)
  • Stage III Merkel Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Stage IV Merkel Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Thyroid Gland Medullary Carcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.